Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid-new results from ABCSG-12_x000D_

Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Kainberger, F; Kaessmann, H; Piswanger-Soelkner, C; Seifert, M; Schippinger, W; Menzel, C; Dubsky, P; Fitzal, F; Steger, G; Greil, R; Marth, C; Kubista, E; Samonigg, H; Jakesz, R; BREAST CANCER RESEARCH AND TREATMENT_x000D_ . 2007. 106: 8-8.

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.

Schippinger, W; Samonigg, H; Schaberl-Moser, R; Greil, R; Thödtmann, R; Tschmelitsch, J; Jagoditsch, M; Steger, GG; Jakesz, R; Herbst, F; Hofbauer, F; Rabl, H; Wohlmuth, P; Gnant, M; Thaler, J; Br J Cancer. 2007; 97(8):1021-1027

A new sesquiterpene lactone sulfate from Reichardia gaditana (Asteraceae)

Zidorn, C; Ellmerer, EP; Heller, W; Johrer, K; Frommberger, M; Greil, R; Guggenberger, M; Ongania, KH; Stuppner, H Z NATURFORSCH B. 2007; 62(1): 132-134.

Erythropoietins in cancer patients: ESMO recommendations for use.

Greil, R; Thödtmann, R; Ann Oncol. 2007; 18 Suppl 2: ii86-ii88.

[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].

Hilbe, W; Aigner, K; Dittrich, C; Eckmayr, J; Fiegl, M; Flicker, M; Forstner, B; Greil, R; Jamnig, H; Krajnik, G; Lang, A; Mohn-Staudner, A; Schinko, H; Studnicka, M; Pirker, R; Ploner, F; Rothmund, J; Schiller, L; Zabernigg, A; Zöchbauer-Müller, S; Wien Klin Wochenschr. 2007; 119(7-8):259-266

Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?

Greil, R; Stein, HJ LANCET ONCOL. 2007; 8(3): 189-190.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz, R; Greil, R; Gnant, M; Schmid, M; Kwasny, W; Kubista, E; Mlineritsch, B; Tausch, C; Stierer, M; Hofbauer, F; Renner, K; Dadak, C; Rücklinger, E; Samonigg, H; J Natl Cancer Inst. 2007; 99(24):1845-1853

Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.

Pleyer, L; Went, P; Russ, G; Prinz, E; Faber, V; Röwert, HJ; Karlbauer, R; Greil, R; WIEN KLIN WOCHENSCHR. 2007; 119(7-8): 254-258.

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

Porschen, R; Arkenau, HT; Kubicka, S; Greil, R; Seufferlein, T; Freier, W; Kretzschmar, A; Graeven, U; Grothey, A; Hinke, A; Schmiegel, W; Schmoll, HJ; J CLIN ONCOL. 2007; 25(27): 4217-4223.

Fulvestrant („Faslodex“) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.

Mlineritsch, B; Psenak, O; Mayer, P; Moik, M; Namberger, K; Hauser-Kronberger, C; Greil, R; BREAST CANCER RES TR. 2007; 106(1): 105-112.